Available online: https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-adults-relapsed-follicular-lymphoma, accessed on 14 September 2017) It is being studied in combination with other drugs for advanced HER2+ breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.